Changes in expression of bone morphogenetic proteins (BMPs), their receptors and inhibin co-receptor betaglycan during bovine antral follicle development: inhibin can antagonize the suppressive effect of BMPs on thecal androgen production

Claire Glister, Leanne Satchell and Philip G Knight

School of Biological Sciences, Hopkins Building, University of Reading, Whiteknights, Reading RG6 6UB, UK

Correspondence should be addressed to P G Knight; Email: p.g.knight@reading.ac.uk

Abstract

We reported previously that bone morphogenetic proteins (BMPs) potently suppress CYP17 expression and androgen production by bovine theca interna cells (TC) in vitro. In this study, real-time PCR was used to analyse gene expression in TC and granulosa cell (GC) layers from developing bovine antral follicles (1–18 mm). Abundance of mRNA transcripts for four BMPs (BMP2, BMP4, BMP6, and BMP7) and associated type I (BMPR1A, BMPR1B, ACVR1 and ACVR1B) and type II (BMPR2, ACVR2A and ACVR2B) receptors showed relatively modest, though significant, changes during follicle development. BMP2 was selectively expressed in GC, while BMP6, BMP7 and betaglycan (TGFBR3) were more abundant in TC. Abundance of betaglycan mRNA (inhibin co-receptor) in TC increased progressively (fivefold; \( P < 0.001 \)) as follicles grew from 1–2 to 9–10 mm. This suggests a shift in thecal responsiveness to GC-derived inhibin, produced in increasing amounts as follicles achieve dominance. This prompted us to investigate whether inhibin can function as a physiological antagonist of BMP action on bovine TC in vitro, in a manner comparable to that for activin signalling. BMP4, BMP6 and BMP7 abolished LH-induced androstenedione secretion and suppressed CYP17 mRNA > 200-fold \( (P < 0.001) \), while co-treatment with inhibin-A reversed the suppressive action of BMP in each case \( (P < 0.001) \). Results support a physiological role for granulosa-derived inhibin as an antagonist of BMP action on thecal androgen synthesis. A shift in intrafollicular balance between thecal BMP signalling (inhibitory for androgen synthesis) and betaglycan-dependent inhibin signalling (stimulatory for androgen synthesis) accords with the physiological requirement to deliver an adequate supply of aromatase substrate to GC of developing follicles.


Introduction

The mechanisms controlling the recruitment, selection, dominance, ovulation and/or regression of follicles in the mammalian ovary have yet to be fully delineated. A multitude of intraovarian factors engage in autocrine/paracrine signalling between theca interna cells (TC), granulosa cells (GC) and oocytes, and contribute to a coordinated programme of follicle cell proliferation and differentiation. Particularly in the later stages of follicle development, intraovarian factors also modulate the sensitivity of follicular cells to gonadotrophins and other extracellular factors (Mihm et al. 2002, Webb et al. 2003). Among this growing list of locally produced regulatory factors are various members of the transforming growth factor-\( \beta \) (TGF\( \beta \)) superfamily, including inhibins, activins and bone morphogenetic proteins (BMPs; reviews: Ying 1988, Knight & Glister 2001, 2006, Welt et al. 2002, Shimasaki et al. 2004).

Numerous studies have documented the spatio-temporal patterns of mRNA and/or protein expression for inhibin/activin \( \alpha/\beta \) subunits (INHA, INHBA and INHBB) during follicle development in several species (reviews: De Jong 1988, Ying 1988, Knight & Glister 2001). To a lesser extent, follicular expression patterns of several BMPs have also been reported (Erickson & Shimasaki 2003, Glister et al. 2004, Shimasaki et al. 2004, Fatehi et al. 2005, Juengel et al. 2006). In addition, functional studies have provided clear evidence that inhibins, activins and BMPs exert local intraovarian roles. For instance, activin and several BMPs can suppress androgen production by cultured TC (Hillier et al. 1991, Dooley et al. 2000, Gister et al. 2005), while inhibin can enhance LH-induced androgen secretion (Hsueh et al. 1987, Hillier et al. 1991, Wrathall & Knight 1995). Activins and BMPs may promote GC proliferation, upregulate FSH receptor expression and enhance oestradiol (E\( 2 \)) production while inhibiting progesterone (P\( 4 \)) production (Hasegawa et al. 1988, Xiao et al. 1992, Findlay & Drummond 1999, Gister et al. 2004, Juengel et al. 2006).
In common with other TGFβ family ligands, BMP signalling involves ligand-induced formation of a heteromeric complex with two types of serine/threonine kinase receptors referred to as type I and type II (Massague & Chen 2000, Miyazono et al. 2000, Miyazawa et al. 2002). In a combinatorial manner, different BMP ligands bind to one of four different type I receptors such as ACVR1 (ALK2), BMPR1A (ALK3), ACVR1B (ALK4) and BMPR1B (ALK6), before recruiting one of three type II receptors (BMPR2, ACVR2A and ACVR2B) to form an active signalling complex. With regard to type I receptors, evidence suggests that BMP2 and BMP4 preferentially bind BMPR1A and/or BMPR1B, while BMP6 and BMP7 tend to bind ACVR1 and/or BMPR1B (ten Dijke et al. 1994, Ebisawa et al. 1999, Aoki et al. 2001). With regard to type II receptors, BMP6, BMP7 and activin preferentially recruit ACVR2A, while BMP2, BMP4, BMP6, BMP7 and BMP15, but not activin, recruit BMPR2 (Liu et al. 1995, Nohno et al. 1995, Yamashita et al. 1995, Ebisawa et al. 1999, Moore et al. 2003). Signalling complex formation leads to the type II receptor transphosphorylating (activating) the intracellular kinase domain of the type I receptor, which, in turn, phosphorylates BMP-responsive transcription factors SMADs 1/5/8. These associate with a common partner SMAD (SMAD4) and translocate to the nucleus to modify target gene expression (Miyazono et al. 2005, 2010).

Inhibins antagonize the biological effects of activins by binding to activin type II receptors thus inhibiting the formation of activin-induced signalling complexes and subsequent activation of activin-responsive SMADs 2/3 (Harrison et al. 2004). For effective presentation of inhibin to type II activin receptors’ co-expression of another cell surface molecule, betaglycan (also known as TGFBR3) is essential. Thus, betaglycan functions as an important co-receptor for inhibin as well as TGFβ, greatly enhancing the efficacy of both ligands. Betaglycan is abundantly expressed on the surface of many cell types, and a soluble form may also be generated by proteolytic cleavage of the membrane-bound receptor (Cook et al. 2004).

In addition to its classical role as an activin antagonist, inhibin may also function as a competitive antagonist of BMPs through the same betaglycan-dependent mechanism, involving competition between inhibin and BMPs for type II receptor(s) utilized by BMPs (Wiater & Vale 2003, Farnworth et al. 2006). Thus, betaglycan and inhibin have emerged as potentially important players in the regulation of BMP signalling, although the extent to which this may apply in the ovarian follicle has not been addressed.

Immunocytochemical studies on bovine ovarian cells in primary culture have documented the expression of multiple BMP ligands and BMP-responsive type I and type II receptors (Glister et al. 2004). However, information is lacking on the extent to which cellular expression of different BMP ligands and their receptors varies during bovine follicle development. With the above points in mind, the initial objective of this study was to use real-time PCR for a detailed analysis of ex vivo gene expression profiles for a range of BMPs, inhibin/activin subunits, their type I and type II signalling receptors and the inhibin co-receptor betaglycan in GC and TC layers isolated from developing bovine antral follicles. The changes we observed in betaglycan expression in TC, together with the aforementioned reports from studies using immortalized testicular, adrenocortical and gonadotroph cell lines (Wiater & Vale 2003, Farnworth et al. 2006), prompted us to use our bovine TC culture model to test the hypothesis that inhibin antagonizes the suppressive effect of BMPs on follicular androgen production.

**Results**

**Pre-screening of follicle samples included in the analysis**

Overall, 24/118 (20%) of samples (from pooled or individual follicles) prepared for gene expression analysis were rejected and excluded from the study because they did not meet our quality control criterion of <5% GC/TC cross-contamination as evidenced by relative expression levels of cell-specific ‘marker’ transcripts (TC marker: CYP17; GC markers: FSHR and CYP19). Following this screening process, respective n values were 4, 5 and 5 for 1–2, 3–4 and 5–6 mm follicle pools and 8, 7, 9 and 9 for individual follicles in the 7–8 mm, 9–10 mm, large (11–18 mm) oestrogen-active (LEA) and large (11–18 mm) oestrogen-inactive (LEI) categories (see Materials and Methods section for further details).

**Follicular fluid steroid concentrations in developing antral follicles**

Figure 1 shows the follicular fluid concentrations (ng/ml) of P₄, androstenedione (A₄) and E₂ in the antral follicle set analysed. A progressive increase (P < 0.001) in E₂ concentration accompanied follicle development to the LEA stage, and this was associated with a concomitant decline in A₄ (P < 0.001), reflecting increased aromatization by follicular GC. In comparison with LEA follicles, LEI follicles had approximately eightfold lower E₂ (P < 0.01), approximately fourfold higher P₄ (P < 0.05) and approximately twofold higher A₄ (P > 0.05; NS) concentrations.

**mRNA expression profiles for gonadotrophin receptors, key steroidogenic enzymes and INHBA subunit in developing antral follicles**

The observed patterns of mRNA expression for FSHR, LHCGR, CYP19, CYP17 and INHBA in GC and TC of developing antral follicles accorded with expectations (Fig. 2). FSHR mRNA was abundant in GC throughout
Developmental changes in the relative abundance of mRNA transcripts for BMP2, BMP4, BMP6 and BMP7 in antral follicles were shown in Fig. 3. Overall, BMP2 mRNA was selectively expressed in GC (P<0.0001), while BMP4, BMP6 and BMP7 transcripts were more abundant in TC than in GC (P<0.0001). In GC, BMP2 mRNA abundance was much lower in LEA follicles than in other follicle categories (P<0.05 compared with 3–4, 5–6 and 7–8 mm follicles; NS compared with 1–2 mm, 9–10 mm and LEI follicles), while in TC, BMP2 mRNA was maximal in LEA follicles (P<0.05 compared with 1–2 mm, 2–3 mm, 5–6 mm, 7–8 mm and LEI follicles). In GC, BMP4 mRNA level was highest in large (11–20 mm) follicles regardless of E:P ratio; in TC, BMP4 mRNA level was approximately twofold higher in larger (7–18 mm) follicles than in 1–6 mm follicles (P<0.05). The relative abundance of BMP6 mRNA in GC or in TC did not vary across follicle development. Likewise, BMP7 transcript abundance in TC was uniform. However, BMP7 expression in GC was lowest in 7–8 mm follicles (P<0.05 compared with 1–2 and 11–18 mm follicles).

Expression profiles for BMP2, BMP4, BMP6 and BMP7 mRNAs in developing antral follicles

Developmental changes in the relative abundance of mRNA transcripts for BMP2, BMP4, BMP6 and BMP7 in antral follicles are shown in Fig. 3. Overall, BMP2 mRNA was selectively expressed in GC (P<0.0001), while BMP4, BMP6 and BMP7 transcripts were more abundant in TC than in GC (P<0.0001). In GC, BMP2 mRNA abundance was much lower in LEA follicles than in other follicle categories (P<0.05 compared with 3–4, 5–6 and 7–8 mm follicles; NS compared with 1–2 mm, 9–10 mm and LEI follicles), while in TC, BMP2 mRNA was maximal in LEA follicles (P<0.05 compared with 1–2 mm, 2–3 mm, 5–6 mm, 7–8 mm and LEI follicles). In GC, BMP4 mRNA level was highest in large (11–20 mm) follicles regardless of E:P ratio; in TC, BMP4 mRNA level was approximately twofold higher in larger (7–18 mm) follicles than in 1–6 mm follicles (P<0.05). The relative abundance of BMP6 mRNA in GC or in TC did not vary across follicle development. Likewise, BMP7 transcript abundance in TC was uniform. However, BMP7 expression in GC was lowest in 7–8 mm follicles (P<0.05 compared with 1–2 and 11–18 mm follicles).

Figure 1 Concentrations (ng/mg protein) of progesterone (P₄), androstenedione (A₄) and oestradiol (E₂) in follicular fluid samples from developing bovine antral follicles. Follicles in the 11–18 mm size class have been subdivided on the basis of oestrogen to progesterone ratio (E:P ratio) as ‘oestrogen-active’ (E:P ratio > 1) or ‘oestrogen-inactive’ (E:P ratio < 1). Values are means, and bars indicate s.e.m. (n=4–9). P values from ANOVA are indicated.

Figure 2 Changes in relative abundance of mRNA transcripts for gonadotrophin receptors (FSHR and LHCGR), steroidogenic enzymes (CYP17 and CYP19) and inhibin/activin βA subunit (INHBA) in theca and granulosal compartments of developing bovine antral follicles. Follicles in the 11–18 mm size class have been subdivided on the basis of oestrogen to progesterone ratio (E:P ratio) as ‘oestrogen-active’ (E:P ratio > 1) or ‘oestrogen-inactive’ (E:P ratio < 1). Values are means, and bars indicate s.e.m. (n=4–9). Results of two-way ANOVA are summarized.
expression in GC increased with follicle size ($P<0.05$; 1–2 vs 9–10 mm follicles), whereas expression in TC decreased with follicle size ($P<0.05$; 1–2 vs 11–18 mm follicles). ACVR1 expression in GC also increased with follicle size ($P<0.05$; 1–2 vs 11–18 mm follicles), while expression in TC fell in LEA follicles ($P<0.05$) compared with all follicles <10 mm). There were no significant differences in ACVR1B expression among different follicle categories. With respect to type II receptors, BMPR2 mRNA level in GC increased progressively from 1–2 to 11–18 mm follicle categories ($P<0.01$) but did not differ between LEA and LEI follicles. Conversely, BMPR2 mRNA level in TC fell from 5–6 mm to LEA follicles ($P<0.05$) and was lower in LEA follicles than in LEI follicles ($P<0.05$). GC abundance of ACVR2A mRNA increased from 1–2 to 9–10 mm follicles (approximately twofold; $P<0.05$) before falling again in LEA follicles (~50%; $P<0.05$) but not LEI follicles. Expression of ACVR2B mRNA did not vary significantly across follicle development for either cell type.

**mRNA expression profile for betaglycan (TGFBR3) in developing follicles**

As shown in Fig. 4, betaglycan mRNA was much more abundant in TC than in GC at all follicle stages examined ($P<0.0001$). In both cell types, betaglycan mRNA level increased progressively (approximately fivefold; $P<0.001$) as follicles grow from 1–2 to 9–10 mm. Levels in TC then fell ($P<0.05$) by about 50% in 11–18 mm follicles, whereas levels in GC remained high. There was no significant difference in betaglycan transcript abundance between LEA and LEI follicles.

**Immunostaining of BMP ligands, receptors and betaglycan in ovary sections**

To reinforce the above mRNA expression data, bovine ovary sections were immunostained with antibodies against each of the BMP ligands and receptors analysed by real-time PCR. Figure 5 shows the distribution of immunoreactive BMP ligands, BMP/activin receptors and betaglycan in the granulosa and theca layers of small antral follicles (~3–5 mm diameter). BMP2 and BMP4 immunoreactivity appeared more abundant in the GC layer, while BMP6 and BMP7 immunoreactivity was evident in both GC and TC layers. Similarly, immunoreactivity for each of the seven signalling receptors and betaglycan was evident in both GC and TC layers.

**Correlations among expression levels of different transcripts in GC of developing follicles**

Figure 6 is a correlation matrix showing the pairwise relationships between follicle diameter, $E_2:P_4$ ratio and relative abundance of each transcript in GC.

---

**Expression profiles for BMP receptor mRNAs in developing antral follicles**

Overall, the abundance of transcripts for the four type I ($BMPR1A$, $BMPR1B$, $ACVR1$ and $ACVR1B$) and three type II ($BMPR2$, $ACVR2A$ and $ACVR2B$) signalling receptors examined showed relatively little variation during follicle development (Fig. 4), and all seven receptors were expressed by both cell types at all follicle stages examined. However, with respect to type I receptors, $BMPR1A$ mRNA level in GC was highest in LEA follicles, whereas $BMPR1A$ mRNA level in TC was lowest in LEA follicles ($P<0.05$). $BMPR1B$ expression in GC increased with follicle size ($P<0.05$; 1–2 vs 9–10 mm follicles), whereas expression in TC decreased with follicle size ($P<0.05$; 1–2 vs 11–18 mm follicles). ACVR1 expression in GC also increased with follicle size ($P<0.05$; 1–2 vs 11–18 mm follicles), while expression in TC fell in LEA follicles ($P<0.05$) compared with all follicles <10 mm). There were no significant differences in ACVR1B expression among different follicle categories. With respect to type II receptors, BMPR2 mRNA level in GC increased progressively from 1–2 to 11–18 mm follicle categories ($P<0.01$) but did not differ between LEA and LEI follicles. Conversely, BMPR2 mRNA level in TC fell from 5–6 mm to LEA follicles ($P<0.05$) and was lower in LEA follicles than in LEI follicles ($P<0.05$). GC abundance of ACVR2A mRNA increased from 1–2 to 9–10 mm follicles (approximately twofold; $P<0.05$) before falling again in LEA follicles (~50%; $P<0.05$) but not LEI follicles. Expression of ACVR2B mRNA did not vary significantly across follicle development for either cell type.

**mRNA expression profile for betaglycan (TGFBR3) in developing follicles**

As shown in Fig. 4, betaglycan mRNA was much more abundant in TC than in GC at all follicle stages examined ($P<0.0001$). In both cell types, betaglycan mRNA level increased progressively (approximately fivefold; $P<0.001$) as follicles grow from 1–2 to 9–10 mm. Levels in TC then fell ($P<0.05$) by about 50% in 11–18 mm follicles, whereas levels in GC remained high. There was no significant difference in betaglycan transcript abundance between LEA and LEI follicles.

**Immunostaining of BMP ligands, receptors and betaglycan in ovary sections**

To reinforce the above mRNA expression data, bovine ovary sections were immunostained with antibodies against each of the BMP ligands and receptors analysed by real-time PCR. Figure 5 shows the distribution of immunoreactive BMP ligands, BMP/activin receptors and betaglycan in the granulosa and theca layers of small antral follicles (~3–5 mm diameter). BMP2 and BMP4 immunoreactivity appeared more abundant in the GC layer, while BMP6 and BMP7 immunoreactivity was evident in both GC and TC layers. Similarly, immunoreactivity for each of the seven signalling receptors and betaglycan was evident in both GC and TC layers.

**Correlations among expression levels of different transcripts in GC of developing follicles**

Figure 6 is a correlation matrix showing the pairwise relationships between follicle diameter, $E_2:P_4$ ratio and relative abundance of each transcript in GC.
Follicle diameter was positively correlated with E₂:P₄ ratio and with GC abundance of mRNAs for CYP19, LHCGR, BMP4, INHA, INHBA, INHBB, betaglycan (TGFBR3) and five of seven BMP/activin receptors. Of the BMP ligand transcripts examined, BMP2 expression was positively associated with BMP4 and BMP6 expression but negatively associated with expression of several established markers of healthy dominant follicles (CYP19, FSHR, INHA, INHBA and INHBB) and with BMPR1A, ACVR1B, BMPR2, ACVR2B and betaglycan expression. There were many positive associations between expression levels of the seven BMP/activin receptors and betaglycan. Notably, there was a very high correlation between BMPR1B and betaglycan mRNA abundance in GC (r=0.91; P<0.0001).

Correlations among expression levels of different transcripts in TC of developing follicles

Figure 7 shows the corresponding pairwise relationships between follicle diameter, E₂:P₄ ratio and relative transcript abundance of 17 different transcripts in TC. There were far fewer significant correlations than in the corresponding GC samples. Nonetheless, follicle diameter was positively correlated with BMP2 transcript abundance and negatively correlated with LHCGR, BMPR1B, ACVR1, ACVR1B and BMPR2 transcript abundance. Follicular E₂:P₄ ratio was negatively correlated with BMPR1A, ACVR1, ACVR1B and BMPR2 transcript abundance in TC. LHCGR mRNA was positively associated with CYP17, BMP6, ACVR1 and BMPR2 mRNA. Among the BMP ligands examined,
there was a strong correlation between BMP2 and BMP4 mRNA abundance ($r=0.88$; $P<0.0001$). Among the seven signalling receptors examined, 10/28 pairwise comparisons yielded significant positive correlations. For instance, BMPR1A was positively correlated with ACVR1, ACVR1B and BMPR2, while BMPR1B was positively correlated with ACVR1B and BMPR2 transcript abundance. Although betaglycan expression was not correlated with follicle diameter when the whole set of follicle samples was considered (see Fig. 7), a significant positive correlation was evident when 11–18 mm follicles were excluded from the analysis ($r=0.50$; $P<0.001$, $n=33$).

Can inhibit reverse the suppressive effect of BMP on thecal androgen production?

The selective expression of betaglycan (inhibin co-receptor) in TC combined with the progressive fivefold increase observed during follicle development from 1–2 to 9–10 mm prompted us to evaluate the possibility that inhibin functions as a physiological antagonist of BMP action on bovine TC, in a manner comparable to that documented for activin signalling. As shown in Fig. 8, BMP4, BMP6 and BMP7 abolished LH-induced $A_4$ secretion ($P<0.01$) and suppressed CYP17 transcript abundance >200-fold ($P<0.001$). Co-treatment with inhibin-A reversed the suppressive action of all three BMPs ($P<0.001$). BMPs also reduced, but to a much lesser degree (two- to ten-fold; $P<0.01$), the levels of three other TC transcripts examined: STAR, CYP11A1 and LHCGR (Fig. 9). In each case, the suppressive effect of BMP was reversed by inhibin ($P<0.01$).

Which signalling receptor subtype(s) mediate the suppressive effect of BMPs on thecal androgen production?

In an attempt to identify at least some of the receptor subtype(s) which mediate the suppressive effect of BMP4, BMP6 and BMP7 on thecal androgen secretion, LH-treated TC were exposed to each BMP in the presence and absence of one of three soluble ‘decoy’ receptors (ectodomains (ECD) of BMPR1A, BMPR1B or ACVR2B). As shown in Fig. 10, the BMPR1A ‘decoy’ receptor selectively blocked the suppressive effect of
BMP4 (P<0.01) without reversing the effect of BMP6 or BMP7. The BMPR1B ‘decoy’ receptor blocked the suppressive effect of both BMP4 and BMP7 (P<0.01) and partially reversed the effect of BMP6 (P<0.1). In contrast, the ACVR2B ‘decoy’ receptor did not affect the response to any of the three BMPs tested, suggesting a low affinity for these ligands.

Discussion

The present study provides novel information on the spatio-temporal mRNA expression profiles for four BMPs (BMP2, BMP4, BMP6 and BMP7), associated type I (BMPR1A, BMPR1B, ACVR1 and ACVR1B) and type II (BMPR2, ACVR2A and ACVR2B) signalling receptors and the inhibin co-receptor betaglycan during bovine antral follicle development. The relative abundance of mRNA transcripts for each of these targets was quantified in GC and TC layers isolated from follicles ranging in diameter from 1 to 18 mm. This size range spans a number of key points in bovine follicle development including ‘cyclic recruitment’ of small antral follicles at ~3–5 mm, dominant follicle ‘selection’ and ‘deviation’ at ~6–8 mm, GC acquisition of LH receptors at ~9–10 mm and dominant oestrogen-active status at 11–18 mm (Ireland et al. 2000, Mihm et al. 2002, Ginther et al. 2003). As expected, follicles in the largest (11–18 mm) size category showed considerable differences in terms of mRNA expression profiles, as reflected by the correlation matrix.
variation in follicular fluid E:P ratio, reflecting their differing ‘health’ status. For this reason, we subdivided these follicles into LEA (presumptive ‘healthy’) and LEI (presumptive ‘regressing’) groups on the basis of their E:P ratio, a widely used means of classifying bovine follicles (Ireland et al. 2000). No attempt was made to subdivide smaller follicles into presumptive ‘healthy’ or ‘regressing’ categories since E:P ratios in FF were well below 1 in all except two follicles (one in the 7–8 mm size class and one in the 9–10 mm size class). Furthermore, in the case of 1–2, 3–4 and 5–6 mm follicles, this was precluded by the pooling of individual follicles for analysis. It should also be noted that since the follicles analysed in this study were from cattle in the mid to late luteal phase of the oestrous cycle, most would belong to the first and/or second post-ovulatory wave of follicle development in which the likely fate of the selected oestrogen-active dominant follicle is regression rather than ovulation (Ireland et al. 2000, Mihm et al. 2002, 2006, Rodgers & Irving-Rodgers 2010).

Analysis of key ‘markers’ of follicle status in the sample set included in the analysis (including follicular fluid E:P ratio and expression of mRNA transcripts for gonadotrophin receptors, steroidogenic enzymes and INHBA subunit) revealed a pattern of expression consistent with previous work (Bao & Garverick 1998, Webb et al. 2004), and confirmed that there was minimal cross-contamination of TC with GC, and vice versa. FSHR mRNA was abundant in GC throughout antral follicle development, consistent with the role of FSH, acting exclusively on GC, in driving antral follicle development (Mihm et al. 2002, Webb et al. 2003). GC expression of LHCGR was only detected in follicles > 9 mm in diameter, consistent with acquisition of LH dependency as they achieve dominance (Bao & Garverick 1998, Webb et al. 2004), which is in agreement with the previous observations. Furthermore, expression levels of LHCGR, CYP19 and INHBA were all maximal in GC of LEA (presumptive ‘healthy’) follicles, being considerably lower in LEI (presumptive ‘regressing’) follicles. Together, the observed cell type and developmental stage-specific expression profiles of key gonadotrophin receptors, steroidogenic enzymes and INHBA subunit support the use of this follicle set to examine the expression pattern of BMP-related transcripts.

BMPs and other TGFβ family members have emerged as potentially important regulators of follicle development (Shimasaki et al. 2004, Knight & Glister 2006). We showed previously that BMP4, BMP6 and BMP7 can act upon both TC and GC in vitro, suppressing LH-induced androgen production by TC (Glister et al. 2005) and enhancing E2, inhibin-A, activin-A and follistatin secretion by GC (Glister et al. 2004). Furthermore, BMP treatment promoted rapid accumulation of phosphorylated SMAD1 in the nuclei of both GC and TC (Glister et al. 2004, 2005) confirming the activation of a functional BMP signalling pathway in these cells.

While previous immunocytochemical evidence for the bovine suggested that BMP4 and BMP7 are confined to TC and BMP6 to GC (Glister et al. 2004), in the present and previous (Kayani et al. 2009) studies, mRNA expression and immunoreactive protein were detected for all three BMPs in both TC and GC layers. BMP4 and BMP7 transcripts were more abundant in TC than in GC in agreement with our earlier immunocytochemical evidence (Glister et al. 2004). However, at the mRNA level, BMP6 expression was much greater in TC than in GC. The explanation for this discrepancy is not known but may reflect a lack of specificity of the antibodies used in the previous study or, possibly, sequestration of BMP6 by TC-derived BMP-binding proteins rendering their epitopes undetectable by the BMP6 antibody used for immunocytochemistry. In any event, mRNA expression levels for BMP6 in each cell type were remarkably uniform across the different follicle stages analysed, perhaps indicating minimal involvement in follicle progression in this species.

Here, we also examined BMP2 expression and showed that mRNA abundance and BMP2 immunoreactivity were much higher in GC than in TC in

Figure 8 Effects of BMP4, BMP6 and BMP7, alone and in combination with inhibin, on (a) androstenedione secretion and (b) CYP17 mRNA expression by bovine TC (note use of log scale on y-axis). Values are means, and bars indicate S.E.M. (n=4 independent cultures). *P<0.05 **P<0.01 and ***P<0.001 versus corresponding value.
agreement with our recent study (Kayani et al. 2009), but contradicting an earlier report (Fatehi et al. 2005) indicating BMP2 expression in TC but not in GC of bovine antral follicles. The reason for this inconsistency is not known but Juengel et al. (2006) also detected BMP2 mRNA by PCR in ovine GC. Moreover, using in situ hybridization, they were able to detect BMP2 mRNA in GC of large regressing follicles but not in GC of large healthy follicles. Interestingly, we found that BMP2 expression in GC fell about tenfold between the 7–8 mm and LEA stage, but was high again in LEI follicles that are presumed to be regressing, as evidenced by their loss of E2- and inhibin-synthesizing capacity. In TC, BMP2 transcript abundance followed an inverse pattern to that seen in GC, although overall expression levels were much lower. Thus, low GC expression of BMP2 (but not BMP4, BMP6 or BMP7) appears to be an additional ‘marker’ of a healthy dominant follicle. This is further supported by the negative correlation between BMP2 and other key GC transcripts up-regulated in LEA follicles including CYP19, INHA, INHBA and INHBB. Within the context of intrafollicular paracrine signalling between GC and TC, we speculate that diminished production of BMP2 by GC of large E2-active follicles might facilitate thecal androgen production.

With regard to BMP/activin receptors, mRNA transcripts and positive immunoreactivity for each of the seven receptors were detected in both GC and TC layers at all follicle stages. Previously, we examined expression of five of these receptors using immunocytochemistry and confirmed that all five were present in both cultured bovine TC and GC (Glister et al. 2004). Our data are also consistent with the findings of Fatehi et al. (2005) who detected mRNA transcripts for BMPR1A, BMPR1B, ACVR1, ACVR1B and BMPR2 in both GC and TC layers of bovine antral follicles but did not examine ACVR2A or ACVR2B expression. Similarly, Souza et al. (2002) detected immunoreactive BMPR1A, BMPR1B and BMPR2 in both GC and TC layers of sheep antral follicles. Overall, among the type I receptors examined by QPCR in the present study, BMPR1B and ACVR1B transcripts were more abundant in GC, while ACVR1 was more abundant in TC. Among type II receptors, ACVR2A was higher in GC, while ACVR2B was higher in TC.

With respect to follicle developmental stage, observed changes in receptor transcript abundance were generally
modest. However, two-way ANOVA indicated that TC and GC displayed quite different follicle stage-dependent expression patterns for five of the receptors (BMPR1A, BMPR1B, ACVR1, BMPR2 and ACVR2A). Indeed, the abundance of three of these transcripts in TC (BMPR1B, ACVR1 and BMPR2) as well as ACVR1B was negatively correlated with follicle diameter, while in GC, abundance of four of the above transcripts (BMPR1B, ACVR1, ACVR1B and BMPR2) as well as BMPR1A was positively correlated with follicle diameter. In particular, both BMPR1B and BMPR2 expression increased progressively in GC while decreasing slightly in TC. This suggests a progressive shift in the balance of GC/TC responsiveness to an intrafollicular BMP ligand(s) that signals via this particular combination of type I and type II receptors, with GC becoming more responsive as follicles increase in size while TC become less responsive. Ligands known to recruit this combination of type I and type II signalling receptors include BMP2, BMP4, BMP6, BMP7 and BMP15 (ten Dijke et al. 1994, Liu et al. 1995, Nohno et al. 1995, Yamashita et al. 1995, Ebisawa et al. 1999, Aoki et al. 2001, Moore et al. 2003).

As a step towards identifying which particular signalling receptors mediate the BMP-induced suppression of androgen production by bovine TC (Glister et al. 2005), we attempted to use a soluble ‘decoy’ receptor approach. Our finding that a soluble ECD of BMPR1A could selectively abolish the effect of BMP4, while soluble ECD of BMPR1B could block the effects of BMP4 and BMP7 (while partially reversing the effect of BMP6), supports the involvement of both of these type I receptors. Evidently, BMP4 binds strongly to both BMPR1A and BMPR1B, while BMP7 binds to BMPR1B but not to BMPR1A. A comprehensive analysis of the effects of different combinations of soluble ECD for all seven potential signalling receptors was beyond the scope of this study, but would be a potentially valuable approach for future work. A complementary in vitro strategy would be to use RNA interference to down-regulate the expression of selected combinations of type I and type II receptors before treating the cells with different BMPs.

In contrast to the relatively modest follicle stage-dependent changes in BMP ligands and their type I and type II signalling receptors, we found that expression of betaglycan (TGFBR3) mRNA followed a distinct pattern during follicle development. Not only was betaglycan transcript abundance much greater in TC than in GC but its expression increased approximately fivefold in a stepwise fashion as follicles grew, reaching a peak in TC of 9–10 mm follicles before falling about 50% in the largest size class (11–18 mm), irrespective of oestrogenic status. We confirmed that betaglycan immunoreactivity was present in both the TC and GC layers of bovine antral follicles and in cultured bovine TC. Since betaglycan is considered an essential co-receptor required to facilitate the presentation of inhibin to type II signalling receptors and hence disrupt activin signalling (Lewis et al. 2000, Chapman et al. 2002, Makanji et al. 2008), this observation prompted us to use our bovine TC culture model to evaluate the possibility that GC-derived inhibin functions as a physiological antagonist of BMP signalling in the ovary, in a manner comparable to its well-documented role as an activin antagonist.

BMP4, BMP6 and BMP7 each promoted a marked reduction in LH-induced androgen secretion by TC, which is in agreement with previous work (Glister et al. 2005). Real-time PCR revealed that all three BMPs greatly reduced CYP17 expression with lesser reductions in other key TC transcripts (STAR, CYP11a1, LHCGR and HSD3B). When co-treated with inhibin, a dramatic reversal of the BMP-induced reduction in androgen secretion and CYP17 expression was observed. Moreover, the BMP-induced reductions in expression of other TC transcripts (STAR, CYP11a1, LHCGR and HSD3B) were also reversed by inhibin. To our knowledge, this is the first study to show that inhibin can function as a BMP antagonist in an ovarian model. Our evidence concurs with other reports showing that inhibin can antagonize BMP effects on immortalized testicular, adrenocortical and gonadotroph cell lines (Wiater & Vale 2003, Farnworth et al. 2006).

In addition to being secreted into the peripheral circulation to negatively regulate pituitary FSH secretion (De Jong 1988, Bleach et al. 2001, Mihm et al. 2002), GC-derived inhibin may act on TC in a paracrine fashion (Hillier et al. 1991, Wrathall & Knight 1995). As shown previously, inhibin-A levels in bovine follicular fluid increase in parallel with follicle growth (Glister et al. 2006). Here, we show that betaglycan mRNA expression in TC increases progressively during follicle growth from 1 to 10 mm. This suggests that the ability of GC-derived inhibin to interact with neighbouring TC depends on this up-regulation of betaglycan expression in growing follicles. Since BMPs reduce LH-induced androgen production, the action of inhibin would facilitate TC androgen output, required for the subsequent conversion to E2 by GC as follicles progress towards functional dominance.

In summary, we have shown that TC and GC expression of BMP2, BMP4, BMP6 and BMP7 and their associated signalling receptors show relatively modest changes during antral follicle growth in cattle. However, the inhibin co-receptor betaglycan undergoes dynamic changes in mRNA expression levels in TC throughout follicle growth. Inhibin, presumably acting via betaglycan, can reverse the suppressive action of BMPs on androgen production and expression of key steroidogenic genes. Further experiments are required to explore these putative interactions of inhibin, betaglycan and BMPs in the ovarian follicle. In addition, information is required on the follicular expression patterns of extra-cellular BMP binding proteins and on the endocrine and/or local factors that modulate the expression of these potentially important regulators of BMP signalling.
Materials and Methods

All media and reagents were purchased from Sigma UK Ltd (Pool, Dorset, UK) or Fisher Scientific Ltd (Loughborough, Leicestershire, UK) unless stated otherwise.

Ovaries and isolation of granulosa and theca cells for ex vivo analysis of gene expression

Ovaries from non-pregnant cattle slaughtered at random stages of the oestrous cycle were collected from an abattoir and transported to the laboratory on ice in medium-199 supplemented with 1% (v/v) antibiotic–antimycotic solution. The stage of the oestrous cycle (I–IV) was estimated by the morphological appearance of the corpus luteum (Ireland et al. 1980), and only ovaries judged to be from cattle in the mid to late luteal phase of the cycle (stage II–III; days 5–17) were selected for follicle dissection. Follicles ranging in diameter from 1 to 18 mm were dissected out from ovaries and sorted according to size. Any follicles showing obvious signs of degeneration were discarded at this stage. Individual follicles in the 1–2 mm (ten follicles per pool, n = 6 pools collected), 3–4 mm (six follicles per pool; n = 7 pools collected) and 5–6 mm (six follicles per pool; n = 6 pools collected) categories were combined for further analysis, while all follicles >7 mm in diameter were processed and analysed individually. Smaller follicles, pooled as above, were hemisected into 1 ml of DPBS, and the interior of the follicle was gently scraped to remove the GC layer. After removing any cumulus–oocyte complexes from the Petri dish, the resulting suspensions were transferred to microcentrifuge tubes and briefly centrifuged (2 min, 2300 g) to pellet the cells. Supernatants (follicular fluid and DPBS) were removed and stored for subsequent analysis of steroids and total protein content. With larger follicles (>7 mm), a sample of follicular fluid was aspirated using a needle and syringe before hemisection and recovery of GC as above. The remaining follicle halves (devoid of most of their GC) were then shaken vigorously in DPBS, and the media were changed three times to remove any remaining GC. Theca interna cell (TC) layers were then peeled away from the follicle halves with the aid of a dissecting microscope as described previously (Glister et al. 2005). Peeled TC layers were briefly centrifuged to remove any dissecting medium. All GC and TC pellets were homogenized in 0.5 ml of TRI Reagent before snap freezing and storage at −80 °C for subsequent RNA purification and cDNA synthesis.

Theca cell culture

For in vitro experiments, TC layers pooled from ~ 50 follicles (4–6 mm diameter) per culture were collected as above and further processed as described by Glister et al. (2005) to obtain individual cell suspensions. The serum-free culture medium used throughout was McCoy’s 5A modified medium supplemented with 1% (v/v) antibiotic–antimycotic solution, 10 ng/ml insulin (bovine pancreas), 2 mM l-glutamine, 10 mM HEPES, 5 µg/ml aprotinin, 5 ng/ml sodium selenite and 0.1% (w/v) BSA. Cells were seeded at a density of 75 000 viable cells/50 µl culture medium into 96-well tissue culture plates (Nunclon, Life Technologies Ltd, Paisley, UK) containing 200 µl/well pre-equilibrated culture medium. Culture plates were incubated in a water-saturated atmosphere of 5% CO2 and 95% air at 38.5 °C for a period of 6 days. Cell-conditioned medium was removed every 48 h, and wells were replenished with fresh medium containing treatments (see below). Conditioned media were stored at −20 °C for steroid immunoassays. At the end of the 144 h culture period, viable cell number was determined using neutral red uptake assay (Campbell et al. 1996, Glister et al. 2001).

RNA isolation from cultured TC

In culture experiments in which total RNA was to be extracted for PCR analysis, cells were seeded into 24-well plates (0.5 × 10⁶ cells/ml) with three replicate wells per treatment. At the end of culture, cell lysates were prepared using TRI Reagent, and pooled lysates from duplicate wells were stored at −80 °C until total RNA isolation.

Preparation and addition of treatments

Ovine LH (NIADDK oLH-S-16) was provided by the National Hormone and Pituitary Program (Torrance, CA, USA). Recombinant human (rh) BMP4, BMP6 and BMP7 and three soluble BMP receptor ECD-Fc fusion protein constructs (BMPR1A, BMPR1B and ACVR2B) were purchased from R&D Systems (Abingdon, Oxon, UK). Bovine 32 kDa inhibin-A was purified from bovine follicular fluid in this laboratory as described previously (Knight et al. 1990). Treatments were sterilized by passing through 0.2 µm filters before further dilution in sterile culture medium. Each treatment was added at 25 µl per culture well, and an equal volume of culture medium alone was added to the control wells.

Hormone assays

Concentrations of A4 in TC-conditioned media and follicular fluid samples were determined by RIA as reported previously (Wrathall & Knight 1995, Glister et al. 2005). The detection limit was 100 pg/ml, and intra- and inter-assay coefficients of variation (CV) were 7 and 10% respectively. Concentrations of P₄ in follicular fluid samples and TC-conditioned media were determined by competitive ELISA (Sauer et al. 1986, Bleach et al. 2001). The detection limit was 20 pg/ml, and intra- and inter-assay CV values were 8 and 10% respectively. Concentrations of E₂ in follicular fluid samples were determined by RIA (Tannetta et al. 1998) with a detection limit of 2 pg/ml and intra- and inter-assay CV values of 6 and 9% respectively.

Purification of RNA, cDNA synthesis and real-time PCR

Total RNA was isolated from tissue samples and cultured TC using TRI Reagent (Sigma UK Ltd) according to the supplier’s instructions. After aqueous phase separation, RNA was precipitated in isopropanol and washed in 75% (v/v) ethanol, and the RNA pellet was re-suspended in 50 µl nuclease-free water. Potential genomic DNA contamination was removed
with an RNase-free DNase kit (RQ1; Promega UK Ltd). The TRI Reagent extraction process was repeated, and the final RNA pellet was re-suspended in 20 μl sterile distilled water; RNA quantity and quality were evaluated by spectrophotometry at 260/280 nm. First strand cDNA was synthesized from 1 μg of the mRNA template using the Reverse-iT RT kit (used according to the manufacturer’s protocol; ABgene, Epsom, Surrey, UK) in a 20 μl reaction primed with random hexamers. Primers were designed using Primer Express software (version 1.5; Perkin-Elmer Applied Biosystems, Warrington, Lancs, UK). Primer sequences and accession numbers are shown in Table 1. In primer validation experiments, dissociation curve analysis and agarose gel electrophoresis were used to verify that each selected primer pair generated a single amplicon of the predicted size. cDNA template dilution curves were used to demonstrate satisfactory PCR efficiency (> 85%) and linearity. PCR assays were carried out in a volume of 25 μl, comprising 10 μl cDNA template (equivalent to 20 ng reverse-transcribed RNA), 1 μl each forward and reverse primers (final concentration 0.4 μM) and 12 μl Quantitect SYBR Green QPCR 2X ‘hot start’ Master Mix (Qiagen). Samples were processed for 40 cycles on an ABI PRISM 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems) with the following thermal cycling conditions: 15 min at 95 °C (one cycle only) then 15 s at 95 °C and 1 min at 60 °C (40 cycles). The ΔΔCt method was used for semi-quantitative comparison of the abundance of each mRNA transcript. ΔCt values for each transcript in a given sample were first normalized to β-actin Ct value (which was uniform across all experimental groups: ANOVA P > 0.1). For cell culture experiments, the resultant ΔΔCt values for each treatment were then normalized to the ΔCt value of the respective vehicle-treated control group. For ex vivo tissue samples, ΔCt values for each transcript in a given sample were normalized to the mean ΔCt value for that transcript in all tissue samples. For graphical presentation, ΔΔCt values were finally converted to fold differences using the formula: fold difference = 2−ΔΔCt.

**Immunohistochemistry**

Ovaries were fixed for 24 h in neutral-buffered formalin, dehydrated and embedded in paraffin wax. Pairs of adjacent sections (6 μm) were mounted onto poly-L-lysine-coated slides (Polysene, Fisher), dewaxed and rehydrated. Endogenous peroxidase activity was quenched by incubation for 30 min in 0.3% v/v hydrogen peroxide in methanol. Microwave antigen retrieval was performed using citrate buffer (10 mM, pH 6). After cooling, tissue sections were washed (PBS + 0.1% (v/v) Tween 20) and blocked for 1 h using 2.5% (v/v) horse serum (ImmPRESS Kit, Vector Laboratories, Peterborough, UK). The following primary antibodies (and appropriately matched control serum/purified IgG for adjacent tissue section) were diluted in blocking buffer and incubated with sections overnight at 4 °C: rabbit anti-BMP2 (Peprotech EC Ltd, London, UK) at 5 μg/ml; mouse anti-BMP4 (clone 66119; R&D Systems) at 5 μg/ml; mouse anti-BMP6 (clone 74219, R&D Systems) at 20 μg/ml; rabbit anti-BMP7 (Peprotech) at 20 μg/ml; rabbit anti-beta-glycan (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) at 1/50; rabbit anti-ACVR1, ACVR1B and ACVR2B (gifts from Prof. C-H Heldin, Ludwig Institute, Uppsala, Sweden) each at 1/100; rabbit anti-ACVR1, ACVR1B, ACVR2A and ACVR2B (raised ‘in-house’ against synthetic peptides conjugated to PPD) each at 1/100. Peptide sequences corresponded to residues 81–89, 55–63, 91–100 and 90–99 within the extracellular domains of the respective bovine activin receptors, and were synthesized and conjugated by Prof. N P Groome and Dr M Cranfield (Oxford Brookes University, UK). After incubation with primary antibody, slides were washed thoroughly in PBS/Tween, and the ImmPRESS Universal anti-mouse/rabbit IgG HRP polymer-based detection system (Vector Laboratories) was used with diaminobenzidine substrate according to the manufacturer’s instructions. Sections were counterstained with haematoxylin, dehydrated and mounted under glass coverslips. Slides were viewed on a Zeiss Axioskop 2 microscope

### Table 1 List of primers used for real-time PCR.

<table>
<thead>
<tr>
<th>Target</th>
<th>Accession number</th>
<th>Forward primer 5′-3′</th>
<th>Reverse primer 5′-3′</th>
<th>Amplicon size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMP2</td>
<td>XM_866011.1</td>
<td>CAAGAGCCGAGTGCGGATTAGCA</td>
<td>TCTTTTCACCGGTCGCAAAAGT</td>
<td>101</td>
</tr>
<tr>
<td>BMP4</td>
<td>NM_001045877.1</td>
<td>TATGAGGCTGTGAAGACCCCCCGCC</td>
<td>AGTTCCTCCACCGCTACATTGTC</td>
<td>104</td>
</tr>
<tr>
<td>BMP6</td>
<td>XM_600972.2</td>
<td>GAGCCGCGAGACCAAGATGTCTCC</td>
<td>TCTAGCCGTCTCGACGATTGCG</td>
<td>108</td>
</tr>
<tr>
<td>BMP7</td>
<td>XM_612246.2</td>
<td>TGGGTTGGAGAAGCTTGGACGCAA</td>
<td>GGGCACTCTCTGGCTCTGGAC</td>
<td>130</td>
</tr>
<tr>
<td>INHA</td>
<td>NM_174094.3</td>
<td>GAGCCGCGAGACCAAGATGTCTCC</td>
<td>TCTAGCCGTCTCGACGATTGCG</td>
<td>108</td>
</tr>
<tr>
<td>INHBB</td>
<td>NM_176852.1</td>
<td>CAGAGGAGCCGAGTGCGGATTAGCA</td>
<td>TCTTTTCACCGGTCGCAAAAGT</td>
<td>101</td>
</tr>
<tr>
<td>INHBA</td>
<td>NM_174363.1</td>
<td>CAGAGGAGCCGAGTGCGGATTAGCA</td>
<td>TCTTTTCACCGGTCGCAAAAGT</td>
<td>101</td>
</tr>
<tr>
<td>INHA</td>
<td>NM_174381.1</td>
<td>ATTGCCTCAGTCGATGCCCAGACCA</td>
<td>CAGACACCTATGCCACAAATGC</td>
<td>105</td>
</tr>
<tr>
<td>LHCGR</td>
<td>NM_174381.1</td>
<td>ATTGCCTCAGTCGATGCCCAGACCA</td>
<td>CAGACACCTATGCCACAAATGC</td>
<td>105</td>
</tr>
<tr>
<td>ACVR1</td>
<td>NM_176663.2</td>
<td>CACGCTCTCGTCTGTGTTGTTGTCG</td>
<td>GGGCACTCTCCACCGACGTTGCG</td>
<td>103</td>
</tr>
<tr>
<td>ACVR1B</td>
<td>XM_586402.2</td>
<td>GGGCACTCTCGTCTGTGTTGTTGTCG</td>
<td>GGGCACTCTCCACCGACGTTGCG</td>
<td>103</td>
</tr>
<tr>
<td>ACVR2A</td>
<td>NM_174227.2</td>
<td>CACGCTCTCGTCTGTGTTGTTGTCG</td>
<td>GGGCACTCTCCACCGACGTTGCG</td>
<td>103</td>
</tr>
<tr>
<td>ACVR2B</td>
<td>NM_174495.2</td>
<td>CACGCTCTCGTCTGTGTTGTTGTCG</td>
<td>GGGCACTCTCCACCGACGTTGCG</td>
<td>103</td>
</tr>
<tr>
<td>TGFBR3</td>
<td>XM_001253071.2</td>
<td>CACGCTCTCGTCTGTGTTGTTGTCG</td>
<td>GGGCACTCTCCACCGACGTTGCG</td>
<td>103</td>
</tr>
<tr>
<td>LHCGR</td>
<td>NM_174381.1</td>
<td>ATTGCCTCAGTCGATGCCCAGACCA</td>
<td>CAGACACCTATGCCACAAATGC</td>
<td>105</td>
</tr>
<tr>
<td>INHBA</td>
<td>NM_174304.1</td>
<td>CACGCTCTCGTCTGTGTTGTTGTCG</td>
<td>GGGCACTCTCCACCGACGTTGCG</td>
<td>103</td>
</tr>
<tr>
<td>INHBB</td>
<td>NM_174305.1</td>
<td>CACGCTCTCGTCTGTGTTGTTGTCG</td>
<td>GGGCACTCTCCACCGACGTTGCG</td>
<td>103</td>
</tr>
<tr>
<td>ACTB</td>
<td>BC102948.1</td>
<td>CACGCTCTCGTCTGTGTTGTTGTCG</td>
<td>GGGCACTCTCCACCGACGTTGCG</td>
<td>103</td>
</tr>
</tbody>
</table>
Statistical analysis

Hormone data were log-transformed before statistical analysis to reduce heterogeneity of variance. QPCR data were analysed as ΔCt values before conversion to relative fold difference values. Results were evaluated using one- and two-way ANOVA and, where indicated or referred to in the text, post hoc pairwise comparisons were made using Fisher’s protected least significant difference (PLSD) test. In vitro results are presented as means ± s.e.m. (n = 4) based on combined data from four independent culture experiments, each using follicle cells harvested from a different set of ovaries.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by the Biotechnology and Biological Sciences Research Council (grants BBS/B/10439 and BB/G017174/1 to P G Knight).

Acknowledgements

We thank Mr D Butlin and Mr S A Feist for assistance with immunohistochemistry, Prof. C-H Heldin (Ludwig Institute for Cancer Research, Uppsala, Sweden) for the gift of antisera against BMP receptors and Prof. N P Groome and Dr M Cranfield (Oxford Brookes University, Oxford, UK) for providing the peptide–PPD conjugates used to raise antisera against activin receptors.

References


Bleich EC, Glencross RG, Feist SA, Groome NP & Knight PG 2001 Plasma inhibin A in heifers: relationship with follicular dynamics, gonadotropins, and steroids during the estrous cycle and after treatment with bovine follicular fluid. Biology of Reproduction 64 743–752. (doi:10.1095/biolreprod64.4.743)


Hsuieh AJ, Dahl KD, Vaughan J, Tucker E, Rivier J, Bardin CW & Vale W 1987 Heterodimers and homodimers of inhibin subunits have different